Skip to main content

Table 1 Patient Characteristics

From: Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer

Characteristics No patients
ECOG performance status
   0 10
   1 11
   2 6
Age, years
   Median 68
   Range 49–88
Men/Women 9/18
Primary cancer
   Colorectal 8
   Breast 12
   Gastric 1
   Pancreas 2
   Others 4
Prior chemotherapy
   No of patients 21
   Range per patient 1–4
Prior radiotherapy 12
Prior endocrine therapy 6
Prior 5-FU 14
No prior therapy 6